Efficacy, Safety, and Satisfaction with the Accu-Chek Insight with Diabeloop Closed-Loop System in Subjects with Type 1 Diabetes: A Multicenter Real-World Study
Authors' conclusion
A significant improvement in glycemic control without serious adverse events and a high degree of patient satisfaction were observed in this first real-world study evaluating the closed-loop system, Accu-Chek Insight with Diabeloop.
Study context
- Population
- Adults with T1D using DBLG1 for at least 3 months; 43 women; age 44.2 ± 11 years; diabetes duration 24.6 ± 12 years; 40 flash and 22 continuous glucose monitoring (CGM); 45 pump and 17 MDI
- Participants
- 62 adults
- Exposure
- DBLG1 closed-loop system: baseline vs after starting
- DBLG1n = 62
- Outcome
- CGM-derived glucose metrics (baseline vs first month)
- Follow-up
- First month
Methodological detailsmulticenter, single-group before-after, Settings adjusted in general toward greater aggressiveness
- Multicenter
- Single-group before-after
- Settings adjusted in general toward greater aggressiveness
Main finding
As reported in the abstract
- %TIR 70-180 mg/dL
- 54.86 ± 17 vs. 72.23 ± 10.11
- %TAR1 180-250 mg/dL
- 26.26 ± 13.3 vs. 19.48 ± 6.78
- %TAR2 > 250 mg/dL
- 12.02 ± 13.09 vs. 6.14 ± 5.23
- %TBR1 54-70 mg/dL
- 5.73 ± 11.5 vs. 1.67 ± 1.3
- %TBR2 < 54 mg/dL
- 1.18 ± 1.97 vs.0.44 ± 0.49
- %CV
- 38.66 ± 7.53 vs. 29.63 ± 3.74
- Median glucose
- 168.57 ± 36 mg/dL vs. 154.63 ± 17.55 mg/dL
- %GMI
- 7.37 ± 0.91 vs. 7.02 ± 0.42
Observational data: associations, not effects.
Further findings
HbA1c (before vs 3 months)
- HbA1c decreased significantly
- 7.45% ± 1.05% vs. 6.95% ± 0.7%
Subgroups by prior therapy or glucose monitoring system
- Similar improvement regardless of prior therapy or glucose monitoring system
Patient satisfaction
- Overall, patient satisfaction was high
Safety
Acute complications, serious adverse events, discontinuation, technical issues
- Acute complications or serious adverse events
- 0
- Discontinued DBLG1
- 3
- Technical issues
- 21
Original publication
Efficacy, Safety, and Satisfaction with the Accu-Chek Insight with Diabeloop Closed-Loop System in Subjects with Type 1 Diabetes: A Multicenter Real-World Study. Diabetes Technol Ther. Published 17 February 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →